Episode
#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
Description
Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering CompoundsDr. Suresh Muthukumaraswamy completed his PhD in Psychology at the University of Auckland in 2005 after which he joined the newly established Cardiff University Brain Research Imaging Centre as a postdoctoral fellow. While at Cardiff, he started research work with psychedelics in 2011 in collaboration with Professor David Nutt and Dr. Robin Carhart-Harris investigating the neuroimaging correlates of the psychedelic drugs psilocybin and LSD. In 2014, Suresh received a prestigious Rutherford Discovery Fellowship and returned to the University of Auckland where he works in the School of Pharmacy at the Faculty of Medical and Health Sciences and leads the Auckland Neuropsychopharmacology Research Group.Suresh’s main research interests are in understanding how therapies alter brain function and behavior and in testing methodologies to measure these changes in both healthy individuals and patient groups — particularly in depressed patients.At the University of Auckland, he has conducted clinical trials in depressed patients involving ketamine, scopolamine, and transcranial magnetic stimulation. He has received several Health Research Council of New Zealand research grants to support this work, including a grant to investigate the effects of microdoses of LSD on brain and cognitive function. Suresh has published 117 papers, with his work receiving 8000+ citations.This special episode of the podcast is a live recording from an event hosted by the Edmund Hillary Fellowship (EHF). EHF began in 2016 as a pilot immigration program and has matured into a fellowship of more than 500 technologists, creatives, investors, entrepreneurs, educators, and systems designers, committed to New Zealand as a base camp for global impact. From more than 50 different nationalities, including New Zealand, fellows span a range of high-value sectors: media, education, cleantech, venture capital, and mental health initiatives/research just to name a few.EHF and its fellows aim to make a meaningful impact in New Zealand/Aotearoa with projects that often have global applications.Please enjoy!*[03:44] Current mental health and addiction trend lines in New Zealand.[05:37] Compounds Suresh has researched.[07:13] Does scopolamine have potential as an antidepressant?[09:55] How ketamine differs from other psychedelics.[16:20] The durability of antidepressant effects.[21:45] How Suresh picks the focus of his research (example: LSD microdosing).[24:43] Why New Zealand is unique for fostering psychedelic innovation.[31:01] How could New Zealand improve the impact of scientific research?[35:13] Inspiring research currently underway in New Zealand.[37:40] Obstacles to getting ketamine labeled as an antidepressant.[40:39] Ketamine research by University of Otago’s Professor Paul Glue.[41:48] Future studies Suresh would like to see (and their challenges).[47:25] The difficulty of applying placebo controls to psychedelic research.[54:49] Getting the public to benefit from this research in a timely manner.[58:17] Risks of microdosing and relying on unregulated supplies.[1:02:21] Open science replication crises.[1:03:56] Training clinical personnel in new science as it becomes available.[1:07:20] Where can New Zealanders access psychedelic therapy now?[1:08:25] Avoiding another 50 years of psychedelic research darkness.[1:13:08] Is any of Suresh’s research focused on addiction recovery?[1:14:08] Why women haven’t been as widely included in these studies as men.[1:15:56] Where aspiring psychedelic researchers should focus their education.[1:17:02] Red flags in the private sector.[1:20:14] Parting thoughts.*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim’s email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim’s books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Chapters
Suresh's research focuses on understanding brain function and behavior in depressed patients, and he has received grants to investigate the effects of microdoses of LSD on brain and cognitive function.
00:00 - 03:53 (03:53)
Summary
Suresh's research focuses on understanding brain function and behavior in depressed patients, and he has received grants to investigate the effects of microdoses of LSD on brain and cognitive function. He is also a clinical advisor to the National Cancer Institute.
Episode#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
PodcastThe Tim Ferriss Show
The use of active placebos in antidepressant medication research helps to show the effectiveness of the placebo effect in treating depression.
03:53 - 14:25 (10:31)
Summary
The use of active placebos in antidepressant medication research helps to show the effectiveness of the placebo effect in treating depression. While conventional SSRIs can take six to eight weeks to show effects, ketamine has a rapid onset in certain individuals.
Episode#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
PodcastThe Tim Ferriss Show
This episode talks about the differences in the therapeutic approaches between psilocybin and ketamine assisted therapy and the lack of studies that have compared the two.
14:25 - 27:42 (13:17)
Summary
This episode talks about the differences in the therapeutic approaches between psilocybin and ketamine assisted therapy and the lack of studies that have compared the two. The guest highlights the importance of addressing root narratives leading to depression for long term antidepressant effects, which has been studied more with psilocybin than ketamine.
Episode#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
PodcastThe Tim Ferriss Show
The potential for New Zealand to carve out specific mental health research funding, similar to Australia's 15 million dollar fund, could push the country as a leader in the field of breakthrough mental health therapeutics.
27:42 - 37:13 (09:30)
Summary
The potential for New Zealand to carve out specific mental health research funding, similar to Australia's 15 million dollar fund, could push the country as a leader in the field of breakthrough mental health therapeutics.
Episode#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
PodcastThe Tim Ferriss Show
The use of ketamine as a depression treatment can be a challenge for some clinicians due to its off-label status and controlled substance classification, but the allowance for S-ketamine to be prescribed on-label may make things easier.
37:13 - 47:13 (10:00)
Summary
The use of ketamine as a depression treatment can be a challenge for some clinicians due to its off-label status and controlled substance classification, but the allowance for S-ketamine to be prescribed on-label may make things easier. There is also some controversy surrounding the importance of the default mode network and downregulation during the ketamine experience.
Episode#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
PodcastThe Tim Ferriss Show
The speaker discusses the potential for breakthroughs in psychedelic research and the need for clinical trials with lightly active placebos.
47:13 - 58:20 (11:06)
Summary
The speaker discusses the potential for breakthroughs in psychedelic research and the need for clinical trials with lightly active placebos. Philanthropic funding has been important in jumpstarting this field of research and securing government grants.
Episode#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
PodcastThe Tim Ferriss Show
Developing a pipeline for training therapists or facilitators to administer psychedelic drugs is extremely controversial due to differing opinions, and the lack thereof may cause a rise in dangerous gray and black market options for treatments.
58:20 - 1:13:32 (15:11)
Summary
Developing a pipeline for training therapists or facilitators to administer psychedelic drugs is extremely controversial due to differing opinions, and the lack thereof may cause a rise in dangerous gray and black market options for treatments. Additionally, there will be attributed suicides and accidents to the use of these drugs, making it important for the Adecayce Foundation and the Harvard Pulse Foundation to continue researching and developing policy focused on psychedelics.
Episode#619: Dr. Suresh Muthukumaraswamy — LSD Microdosing, Classical Psychedelics vs. Ketamine, Science and Speed in New Zealand, Placebo Options, and The Infinite Possibilities of Studying Mind-Altering Compounds
PodcastThe Tim Ferriss Show
The pharmaceutical industry faces tensions around speed, intellectual property, and red flags in every area of development.
1:13:32 - 1:22:01 (08:29)
Summary
The pharmaceutical industry faces tensions around speed, intellectual property, and red flags in every area of development. Additionally, some non-improvements can have negative impacts on the ecosystem and cause issues in manufacturing processes.